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Abstract
The increased speed and decreasing cost of sequencing, along with an understanding of the clinical relevance of
emerging information for patient management, has led to an explosion of potential applications in healthcare. Cur-
rently, SNP arrays and Next-Generation Sequencing (NGS) technologies are relatively new techniques used to scan
genomes for gains and losses, losses of heterozygosity (LOH), SNPs, and indel variants as well as to perform com-
plete sequencing of a panel of candidate genes, the entire exome (whole exome sequencing) or even the whole ge-
nome. As a result, these new high-throughput technologies have facilitated progress in the understanding and
diagnosis of genetic syndromes and cancers, two disorders traditionally considered to be separate diseases but that
can share causal genetic alterations in a group of developmental disorders associated with congenital malformations
and cancer risk. The purpose of this work is to review these syndromes as an example of a group of disorders that
has been included in a panel of genes for NGS analysis. We also highlight the relationship between development and
cancer and underline the connections between these syndromes.
Keywords: NGS, new technologies, developmental syndrome, cancer predisposition.
Introduction
Genetic testing using new technologies, such as
Next-Generation Sequencing (NGS), is transitioning from
the research to the diagnostic phase. Methodologies for
translating new technologies to the clinical setting are not
well established and are currently in the difficult process of
transitioning from a primarily research environment and
culture to a more quality controlled diagnostic environ-
ment. This significant change is having an enormous im-
pact on health, but it is also creating diagnostic dilemmas.
The rapid development of NGS has radically reduced both
the cost and time required for exome or genome analysis
and has allowed for the implementation of panels of genes
for diagnosis and research in both genetic syndromes and
cancer.
The impact of genetics and genomics in health
During the last two decades, developments in genet-
ics and enormous advances in genomic technologies have
altered the capability of understanding diseases, making di-
agnoses and providing effective clinical management.
From a mechanistic point of view, genetic disorders may be
roughly subdivided in three main subtypes: genomic, ge-
netic and epigenetic. Genomic disorders encompass those
diseases in which there is either a gain or loss (sometimes
both) of genomic material. They usually include very large
gains and losses, such as those that are observed in triso-
mies and monosomies, as well as smaller, cryptic, me-
dium-size aberrations, such as those that are observed in
microduplication and microdeletion syndromes. Although
there is no absolute consensus, the term genomic disorders
applies to rearrangements of between 5 kb and several
megabases. Genetic disorders refer to small gains and
losses, usually of 1-5000 bp. Epigenetic disorders are those
without gains and losses that have chemical changes (often
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methylation defects but also acetylation as well as others).
Considering these disorders together (~8000), genomic dis-
orders account for ~8-12% of the cases, genetic disorders
~85-87% and epigenetic disorders ~2-3%. The current vi-
sion of genomics in healthcare and public health represents
a confluence of the development of three important strands:
genetic technologies, clinical genetics and genomic
healthcare. Genetic technologies encompass the whole
range of laboratory technologies that provide detailed se-
quence and other genomic information, whether related to
an individual’s germ-line or somatic cells, that is, the al-
tered genome within cancer cells.
The explosion of potential applications in healthcare
has arisen from the increased speed and decreasing cost of
sequencing, along with an increased understanding of the
clinical relevance of emerging information for patient man-
agement. Currently, SNP arrays and NGS technologies are
relatively new techniques used to scan the genome for gains
and losses and losses of heterozygosity (LOH), SNPs and
indel variants. SNP arrays are proving to be useful tools in
the detection of chromosomal imbalances and LOH in a
wide range of disorders (Miller et al., 2010), and NGS pro-
vides a rapid and complete sequencing of a set of candidate
genes, the entire exome (whole exome sequencing, WES)
and even the whole genome (WGS) (Tucker et al., 2009;
Ng et al., 2010).
Clinical genetics is a specialty that provides services
for individuals and families affected by or at risk of a ge-
netic disorder or congenital abnormality. It includes diag-
nostic assessment, counseling and support, genetic testing
and provision of advice to patients and their extended fam-
ily. Traditionally, clinical genetics has encompassed chro-
mosomal disorders, dysmorphic syndromes, teratogenic
disorders and single gene disorders, which may be evident
in childhood or later in life. The challenge that arises for
clinical genetics is that many inherited disorders, including
a large number of single gene disorders, manifest with a
wide range of clinical symptoms; as a result, clinicians in
some specialties need to be skilled in recognizing, diagnos-
ing and managing these genetic conditions. Genomic
healthcare widens the range of applications of genomic
technologies to include instances where they may be used
to recognize a precise molecular sub-type of disease and
hence fine-tune treatment or determine disease susceptibil-
ity.
The impact of new technologies in genomic
medicine
The prevailing rhetoric amongst basic grant funding
bodies and sponsors, researchers and many policy-makers
worldwide is that genomic medicine represents a revolu-
tion in healthcare, with some even referring to it as “ge-
nomic tsunami.” It is envisaged that the use of genomic
technologies to enable patient diagnosis and treatment
based on information about a person’s entire DNA se-
quence, through WGS, or the portion of the genome that en-
codes proteins, through WES, will become a part of main-
stream healthcare practices. Genomics is having an impact
in many areas of clinical medicine, but it is not so much a
revolution as it is an evolution. Clinical research leaders are
slowly gaining knowledge and experience with these ap-
proaches, and the process of embedding new practices in
high quality care pathways throughout our country is grad-
ual and difficult.
New technologies and clinical knowledge have facili-
tated significant progress in the capability of clinicians to
diagnose and manage genetic and heritable disorders aris-
ing in a wide range of clinical areas. It is believed that this
will be rapidly followed rapidly a burgeoning of “genomic
medicine” in which a wider analysis of genomic informa-
tion will be used to predict, prevent, diagnose and treat
many common chronic and rare disorders. It is important
that the development and configuration of clinical and lab-
oratory genetics and other specialties is optimized to meet
the expected future capacity and range of needs. Such opti-
mization should build on the strengths of existing structures
and processes and should aim to incorporate genomics into
existing clinical pathways. It has been recommended that
relationships between specialty genetic services and a
range of other clinical specialties should be formed as a key
foundation for the development of genomic medicine.
The rapid development of NGS has radically reduced
both the cost and the time required for WES and WGS. The
Human Genome Project took approximately 13 years to se-
quence the first human genome and cost several billion dol-
lars; today, the same process can be completed within
weeks for a few thousand dollars using NGS. Soon it may
be easier and cheaper to sequence an entire genome than to
sequence a single gene or genotype a series of known muta-
tions. Furthermore, using the same technologies, gene ex-
pression profiling and epigenetic analyses are becoming
simpler and cheaper. WES and WGS together with our
evolving knowledge of genes and disease are likely to
change the current practice of medicine and public health
by facilitating more accurate, sophisticated and cost-
effective genetic testing. WES and WGS have several im-
portant clinical applications in the short to medium term:
improved diagnosis and management of diseases with a
strong heritable component as well as personalized diagno-
sis and stratified treatment of cancer through tumor profil-
ing. Over the long term, these technologies may also have
many other applications, including tissue matching, risk
prediction and pharmacogenetics.
Cancer is one of the most prevalent groups of diseases
and is associated with high morbidity and mortality. Spo-
radic Cancer is defined as neoplasias that have a mono-
clonal origin in somatic cells and arise in a person without
family history or any known predisposing genetic alter-
ation. When cancer occurs in family members more fre-
quently than the general population it is known as Familial
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or Hereditary Cancer and is associated with germ-line
DNA alterations that increase the risk of carcinogenesis.
Although the cause of most childhood cancers re-
mains unknown, it has been established that the risk is
higher in children with congenital anomalies and some spe-
cific genetic syndromes. These Cancer Predisposition
Syndromes are generally caused by germ-line mutations in
specific genes that can predispose family members to de-
velop cancer at an early age. These syndromes are rare, and
it has traditionally been estimated that tumors arising in this
context represent 5-10% of childhood tumors; however,
this number seems to be increasing (Schiffman et al.,
2013).
Within cancer predisposition syndromes, there exists
a subgroup characterized by the presence of multiple con-
genital malformations due to developmental defects and a
higher than normal risk of developing tumors. These are re-
ferred to as Genetic developmental syndromes with an in-
creased risk to develop cancer. This group is composed of a
broad spectrum of syndromes with different causes and
clinical features in which the presence of tumors is not al-
ways the most characteristic manifestation. Some of the
main features of these syndromes and the associated genes
are listed in Table 1, and some examples of phenotypic ap-
pearance are shown in Figure 1.
The purpose of this work is to review the main genetic
syndromes associated with congenital malformations and
increased cancer risk as an example of a group of disorders
that has been included in a panel of genes used for NGS
analysis. We also highlight the relationship between devel-
opment and cancer, and underline the connections between
these syndromes.
Cancer-Related and Syndrome-Causing Genes
Recently, studies of genes known to cause genetic
syndromes in the context of their involvement in neoplastic
processes have led to a better understanding of both cancer
and rare diseases. Nevertheless, little is known regarding
how defects in these genes and in signaling pathways can
produce congenital developmental abnormalities as well as
alterations underlying the development of neoplastic pro-
cess. It seems that the relationship between development
and cancer could be the result of inversely related events.
During embryonic development, genetic and epigenetic in-
structions direct growth and differentiation with an orderly
and well-established pattern, while oncogenic alterations
lead to undifferentiated cells in a disorganized and chaotic
pattern (Bellacosa, 2013).
The occurrence of tumors in genetic developmental
syndromes depends on many variables: the molecular path-
way involved (differentiation, proliferation, cell death,
etc.), the affected gene (oncogene, tumor suppressor or
DNA repair gene), the type of alteration (genetic, genomic,
or epigenetic), and the origin of these changes (germ-line or
somatic). This occurrence also explains why a large propor-
tion of developmental defects associated with cancer can be
grouped into a few clusters with overlapping clinical mani-
festations, common molecular pathways, and similar
pathogenic mechanisms (Figure 2).
Overgrowth syndromes, RASopathies,
PTENopathies and AKT/PI3K/mTOR pathway
As shown in Figure 2, these syndromes are repre-
sented by four different clusters but are described here in a
single section because they are closely related and share
many nodes.
Overgrowth Syndromes (OGS) are one of the main
groups of cancer-related developmental syndromes. OGS
are composed of a heterogeneous group of disorders in
which the main feature is that weight, height, and/or head
circumference are 2-3 standard deviations above the mean
for the patient’s sex and age. In some OGS, tumors appear
mostly in the abdominal region, usually before 10 years of
age. Beckwith-Wiedemann syndrome shows a 10% cumu-
lative risk of cancer at 4 years of age; the associated cancers
are generally Wilms tumor and hepatoblastoma, but adre-
nal neuroblastoma and rhabdomyosarcoma have been de-
scribed. In Perlman syndrome, only cases of Wilms tumor
and/or bilateral renal hamartomas have been reported,
while in Sotos syndrome, lympho-hematologic malignan-
cies are more common, followed by Wilms tumor,
sacrococcygeal teratoma, and neuroblastoma (Lapunzina,
2005).
Within OGS there is a well-defined subgroup known
as “RASopathies,” characterized by variable degrees of in-
tellectual deficit, dysmorphic face, cardiac alterations, skin
manifestations, and predisposition to cancer in some cases.
The RAS genes are widely known because of their activa-
tion in 20-30% of human cancers; these genes play an im-
portant role in the RAS/MAPK signaling cascade, translat-
ing extracellular growth stimuli into cellular responses,
with impacts on cell proliferation, differentiation, and
death. Therefore, it is not surprising that disruption of Ras
protein function is involved in the pathogenesis of many
human diseases, including cancer. In addition to somatic
mutations in cancers, mutations in the RAS genes causing a
dysregulation of the RAS/MAPK pathway may also occur
in the germ-line or as a post-zygotic event. Such mutations
lead to the appearance of RASopathies, and the phenotypic
overlap among RASopathies can be explained by alteration
of the same molecular pathway. RASopathies include
Noonan, neurofibromatosis type 1, Costello, LEOPARD
and Cardio-Facio-Cutaneous (CFC) syndromes; some of
these syndromes are associated with an increased risk of
developing cancer (Hafner and Groesser, 2013).
The relationship between genetic alterations and sus-
ceptibility to cancer is not always straightforward. Costello
syndrome patients show tumors in 10-15% of cases diag-
nosed with a mutation in HRAS, and it has been suggested
that the risk is higher in individuals with the G12A muta-
NGS, genetic syndromes and cancer 243
244 Lapunzina et al.
T
a
b
le
1
-
M
ai
n
g
en
et
ic
d
ev
el
o
p
m
en
ta
l
sy
n
d
ro
m
es
w
it
h
in
cr
ea
se
d
ri
sk
to
d
ev
el
o
p
ca
n
ce
r.
O
M
IM
S
y
n
d
ro
m
e
P
re
v
al
en
ce
(/
1
0
0
.0
0
0
)
T
u
m
o
rs
E
ti
o
lo
g
y
H
er
ed
it
y
3
0
4
0
5
0
A
ic
ar
d
i
S
y
n
d
ro
m
e;
A
IC
<
0
.0
1
A
n
g
io
sa
rc
o
m
a,
h
ep
at
o
b
la
st
o
m
a,
ch
o
ro
i
d
p
le
x
u
s
p
ap
il
lo
m
a,
m
ed
u
ll
o
b
la
st
o
m
a,
an
d
em
-
b
ry
o
n
al
tu
m
o
rs
.
P
o
ss
ib
ly
ca
u
se
d
b
y
h
et
er
o
zy
g
o
u
s
m
u
ta
-
ti
o
n
s
in
an
as
y
et
u
n
id
en
ti
fi
ed
X
-l
in
k
ed
g
en
e
in
fe
m
al
es
le
th
al
in
m
al
es
.
P
ro
b
ab
ly
X
-l
in
k
ed
d
o
m
in
an
t
1
1
8
4
5
0
,
6
1
0
2
0
5
A
la
g
il
le
S
y
n
d
ro
m
e;
A
L
G
S
0
.4
*
*
H
ep
at
o
ce
ll
u
la
r
ca
n
ce
r.
T
y
p
e
I:
JA
G
1
m
u
ta
ti
o
n
s
(8
0
-9
0
%
),
2
0
p
1
2
m
ic
ro
d
el
et
io
n
(7
%
).
T
y
p
e
II
:
N
O
T
C
H
2
m
u
ta
ti
o
n
s
(<
1
%
).
A
D
.
D
e
n
o
v
o
m
u
ta
ti
o
n
s
5
0
-7
0
%
.
1
0
6
2
1
0
A
n
ir
id
ia
;
A
N
[W
A
G
R
in
cl
u
d
ed
]
1
.3
8
W
il
m
s’
tu
m
o
r
(6
%
ri
sk
).
P
A
X
6
g
en
e
m
u
ta
ti
o
n
s
ar
e
re
sp
o
n
si
b
le
fo
r
9
8
%
o
f
ca
se
s
o
f
an
ir
id
ia
.
W
A
G
R
is
co
n
ti
g
u
o
u
s
g
en
e
sy
n
d
ro
m
e
(1
1
p
1
3
d
e-
le
ti
o
n
)
in
v
o
lv
in
g
P
A
X
6
,
W
T
1
,
B
D
N
F
an
d
S
L
C
1
A
2
g
en
es
.
A
D
w
it
h
co
m
p
le
te
p
en
et
ra
n
ce
an
d
v
ar
i-
ab
le
ex
p
re
ss
iv
it
y
.
D
el
et
io
n
s
in
W
A
G
R
sy
n
d
ro
m
e
ar
e
ty
p
ic
al
ly
d
e
n
o
v
o
.
2
0
8
9
0
0
A
ta
x
ia
-T
el
an
g
ie
ct
as
ia
;
A
T
1
L
eu
k
em
ia
an
d
ly
m
p
h
o
m
a
(8
5
%
),
as
-
tr
o
cy
to
m
as
,
g
li
o
m
as
,
th
y
ro
id
,
b
re
as
t,
co
lo
n
,
g
as
tr
ic
,
o
v
ar
ia
n
an
d
sk
in
ca
n
ce
r.
A
T
M
m
u
ta
ti
o
n
s
(9
0
%
).
C
y
to
g
en
et
ic
7
;1
4
tr
as
lo
ca
ti
o
n
in
1
0
%
o
f
th
e
st
im
u
-
la
te
d
ly
m
p
h
o
cy
te
s.
A
D
.
H
et
er
o
zy
g
o
te
ca
rr
ie
rs
h
av
e
an
in
-
cr
ea
se
d
ri
sk
o
f
d
ev
el
o
p
in
g
ca
n
ce
r.
1
5
3
4
8
0
B
an
n
ay
an
-R
il
ey
-R
u
v
al
ca
b
a
S
y
n
d
ro
m
e;
B
R
R
S
<
0
.1
H
am
ar
to
m
at
o
u
s
p
o
ly
p
s,
li
p
o
m
as
,
m
e-
n
in
g
io
m
as
,
b
re
as
t,
an
d
th
y
ro
id
ca
n
ce
r.
P
T
E
N
m
u
ta
ti
o
n
s
(6
5
%
)
an
d
d
el
e-
ti
o
n
s/
d
u
p
li
ca
ti
o
n
s
(1
1
%
).
A
D
1
0
9
4
0
0
B
as
al
C
el
l
N
ev
u
s
S
y
n
d
ro
m
e;
B
C
N
S
[G
O
R
L
IN
S
Y
N
D
R
O
M
E
]
1
.8
5
%
d
ev
el
o
p
m
ed
u
ll
o
b
la
st
o
m
a.
P
T
C
H
1
A
D
.
C
au
se
d
b
y
d
e
n
o
v
o
m
u
ta
ti
o
n
s
in
2
0
-3
0
%
o
f
th
e
ca
se
s.
3
0
1
8
4
5
B
az
ex
S
y
n
d
ro
m
e;
B
Z
X
<
0
.0
1
B
as
al
ce
ll
ca
rc
in
o
m
as
.
L
in
k
ed
to
X
q
2
4
-q
2
7
X
-l
in
k
ed
d
o
m
in
an
t
1
3
0
6
5
0
B
ec
k
w
it
h
-W
ie
d
em
an
n
S
y
n
d
ro
m
e;
B
W
S
W
il
m
s’
tu
m
o
r,
h
ep
at
o
b
la
st
o
m
a,
ad
re
n
al
n
eu
ro
b
la
st
o
m
a,
rh
ab
d
o
m
y
o
sa
rc
o
m
a.
1
1
p
1
5
im
p
ri
n
te
d
re
g
io
n
:
H
y
p
o
m
et
h
y
l-
at
io
n
at
D
M
R
2
(5
0
%
),
p
at
er
n
al
u
n
ip
a-
re
n
ta
l
d
is
o
m
y
(2
0
%
),
h
y
p
er
m
et
h
y
la
ti
o
n
at
D
M
R
1
(5
-7
%
)
an
d
p
o
in
t
m
u
ta
ti
o
n
s
in
C
D
K
N
1
C
(5
-1
0
%
o
f
sp
o
ra
d
ic
an
d
4
0
%
o
f
fa
m
il
ia
l
ca
se
s)
.
A
p
p
ro
x
im
at
el
y
1
5
%
o
f
in
d
iv
id
u
al
s
h
av
e
a
fa
m
il
y
h
is
to
ry
co
n
si
st
en
t
w
it
h
A
D
p
at
te
rn
.
R
ec
u
rr
en
ce
ri
sk
is
d
et
er
-
m
in
ed
ac
co
rd
in
g
th
e
u
n
d
er
ly
in
g
g
en
et
ic
m
ec
h
an
is
m
.
2
1
0
9
0
0
B
lo
o
m
S
y
n
d
ro
m
e;
B
L
M
<
0
.0
1
L
eu
k
em
ia
,
ly
m
p
h
o
m
a,
W
il
m
s’
tu
-
m
o
r,
sk
in
,
g
as
tr
ic
,
co
lo
n
,
h
ep
at
o
ce
l-
lu
la
r,
ce
rv
ic
al
an
d
b
re
as
t
ca
n
ce
r.
B
L
M
A
R
2
5
0
2
5
0
C
ar
ti
la
g
e-
H
ai
r
H
y
p
o
p
la
si
a;
C
H
H
<
0
.0
1
In
cr
ea
se
d
m
al
ig
n
an
cy
ri
sk
,
es
p
ec
ia
ll
y
ly
m
p
h
o
m
a
an
d
cu
ta
n
eo
u
s
ca
rc
in
o
m
a.
R
M
R
P
A
R
6
0
1
8
4
7
C
h
o
le
st
as
is
,
P
ro
g
re
ss
iv
e
F
am
il
ia
l
In
tr
ah
ep
at
ic
,
2
;
P
F
IC
2
<
0
.0
1
A
b
o
u
t
1
5
%
o
f
af
fe
ct
ed
d
ev
el
o
p
m
al
ig
-
n
an
t
li
v
er
tu
m
o
rs
,
es
p
ec
ia
ll
y
h
ep
at
o
-
ce
ll
u
la
r
ca
rc
in
o
m
a
an
d
ch
o
la
n
g
io
-
ca
rc
in
o
m
a.
A
B
C
B
1
1
A
R
2
1
8
0
4
0
C
o
st
el
lo
S
y
n
d
ro
m
e
<
0
.0
1
R
h
ab
d
o
m
y
o
sa
rc
o
m
a
(5
9
%
o
f
tu
m
o
rs
),
p
ro
st
at
e
ca
rc
in
o
m
a
(1
3
%
o
f
tu
m
o
rs
)
an
d
n
eu
ro
b
la
st
o
m
a
(9
%
o
f
tu
m
o
rs
).
H
R
A
S
(8
5
%
).
G
1
2
S
(8
0
%
)
an
d
G
1
2
A
ch
an
g
es
ac
co
u
n
t
fo
r
9
5
%
o
f
th
e
d
e-
te
ct
ed
m
u
ta
ti
o
n
s.
A
D
w
it
h
co
m
p
le
te
p
en
et
ra
n
ce
an
d
v
ar
i-
ab
le
ex
p
re
ss
iv
it
y
.
U
su
al
ly
o
cc
u
rs
b
y
d
e
n
o
v
o
m
u
ta
ti
o
n
s.
1
5
8
3
5
0
C
o
w
d
en
D
is
ea
se
;
C
D
0
.4
5
B
re
as
t,
th
y
ro
id
,
en
d
o
m
et
ri
al
an
d
re
n
al
ce
ll
ca
n
ce
r,
ce
re
b
el
la
r
d
y
sp
la
st
ic
g
an
g
li
o
cy
to
m
a,
m
el
an
o
m
a.
P
T
E
N
.
G
er
m
li
n
e
8
0
%
,
p
ro
m
o
te
r
v
ar
ia
-
ti
o
n
s
1
0
%
.
A
D
w
it
h
9
0
%
p
en
et
ra
n
ce
at
2
0
y
ea
rs
,
an
d
v
ar
ia
b
le
ex
p
re
ss
iv
it
y
.
NGS, genetic syndromes and cancer 245
O
M
IM
S
y
n
d
ro
m
e
P
re
v
al
en
ce
(/
1
0
0
.0
0
0
)
T
u
m
o
rs
E
ti
o
lo
g
y
H
er
ed
it
y
1
7
6
4
5
0
C
u
rr
ar
in
o
S
y
n
d
ro
m
e
1
P
re
sa
cr
al
te
ra
to
m
a
M
N
X
1
A
D
1
9
4
0
8
0
D
en
y
s-
D
ra
sh
S
y
n
d
ro
m
e;
D
D
S
<
0
.0
1
N
ep
h
ro
b
la
st
o
m
a
(W
il
m
s
tu
m
o
r)
,
g
o
n
ad
o
b
la
st
o
m
a.
W
T
1
A
D
.
S
o
m
at
ic
m
u
ta
ti
o
n
.
1
0
5
6
5
0
D
ia
m
o
n
d
-B
la
ck
fa
n
A
n
em
ia
;
D
B
A
0
.6
7
*
*
H
ep
at
o
m
a,
ly
m
p
h
o
m
a,
A
L
L
,
A
M
L
,
M
D
S
.
A
ss
o
ci
at
ed
w
it
h
m
u
ta
ti
o
n
s
in
se
v
en
g
en
es
en
co
d
in
g
ri
b
o
so
m
al
p
ro
te
in
s:
R
P
S
1
9
(2
5
%
),
R
P
L
5
(6
.6
%
),
R
P
L
1
1
(4
.8
%
),
R
P
L
3
5
A
(3
%
),
R
P
S
2
4
,
R
P
S
1
7
,
an
d
R
P
S
7
.
A
D
.
5
5
%
-6
0
%
d
e
n
o
v
o
.
2
2
3
3
7
0
D
u
b
o
w
it
z
S
y
n
d
ro
m
e
<
0
.0
1
A
p
la
st
ic
an
em
ia
,
A
L
L
,
ly
m
p
h
o
m
a,
n
eu
ro
b
la
st
o
m
a.
N
o
t
k
n
o
w
n
A
R
2
2
7
6
5
0
F
an
co
n
i
A
n
em
ia
;
F
A
0
.3
A
M
L
(9
%
),
M
D
S
(7
%
),
A
M
L
(1
3
%
b
y
ag
e
5
0
y
ea
rs
),
sq
u
am
o
u
s
ce
ll
ca
rc
in
o
-
m
as
,
h
ep
at
o
m
a.
A
t
le
as
t
1
5
g
en
es
ar
e
as
so
ci
at
ed
w
it
h
d
if
fe
re
n
t
co
m
p
le
m
en
ta
ti
o
n
g
ro
u
p
s.
A
R
,
ex
ce
p
t
fo
r
F
A
N
C
B
,
w
h
ic
h
is
X
-l
in
k
ed
.
1
3
6
6
8
0
F
ra
si
er
S
y
n
d
ro
m
e
<
0
.0
1
G
o
n
ad
o
b
la
st
o
m
a
W
T
1
A
D
.
S
o
m
at
ic
m
u
ta
ti
o
n
.
2
3
0
8
0
0
G
au
ch
er
D
is
ea
se
,
T
Y
P
E
I
1
H
ep
at
o
m
a,
m
u
lt
ip
le
m
y
el
o
m
a,
n
o
n
-
H
o
d
g
k
in
ly
m
p
h
o
m
a.
G
B
A
A
R
w
it
h
v
ar
ia
b
le
ex
p
re
ss
iv
it
y
.
T
h
er
e
is
a
h
ig
h
ca
rr
ie
r
fr
eq
u
en
cy
(1
:1
8
)
in
A
sh
-
k
en
az
i
in
d
iv
id
u
al
s.
2
3
5
0
0
0
H
em
ih
y
p
er
p
la
si
a,
Is
o
la
te
d
;
IH
1
In
cr
ea
se
d
ri
sk
fo
r
em
b
ry
o
n
al
tu
m
o
rs
an
d
W
il
m
s
tu
m
o
r
.
N
o
t
k
n
o
w
n
A
D
6
1
1
9
6
2
H
u
n
te
r-
M
ac
d
o
n
al
d
S
y
n
d
ro
m
e
M
en
in
g
io
m
a.
N
o
t
k
n
o
w
n
A
D
6
0
2
5
0
1
M
ac
ro
ce
p
h
al
y
-C
ap
il
la
ry
M
al
fo
rm
a-
ti
o
n
,
M
-C
M
<
0
.0
1
In
cr
ea
se
d
ri
sk
o
f
m
en
in
g
io
m
a,
W
il
m
s
tu
m
o
r
an
d
le
u
k
em
ia
.
P
IK
3
C
A
S
o
m
at
ic
m
u
ta
ti
o
n
1
7
4
8
0
0
M
cC
u
n
e-
A
lb
ri
g
h
t
S
y
n
d
ro
m
e;
M
A
S
0
.5
5
P
it
u
it
ar
y
ad
en
o
m
a
G
N
A
S
S
o
m
at
ic
m
o
sa
ic
is
m
2
5
7
3
0
0
M
o
sa
ic
V
ar
ie
g
at
ed
A
n
eu
p
lo
id
y
S
y
n
-
d
ro
m
e;
M
V
A
<
0
.0
1
W
il
m
s
tu
m
o
r,
rh
ab
d
o
m
y
o
sa
rc
o
m
a,
le
u
-
k
em
ia
.
B
U
B
1
B
A
R
2
5
3
2
5
0
M
u
li
b
re
y
N
an
is
m
<
0
.0
1
W
il
m
s
tu
m
o
r
T
R
IM
3
7
A
R
1
6
2
2
0
0
N
eu
ro
fi
b
ro
m
at
o
si
s,
T
Y
P
E
I;
N
F
1
2
3
M
al
ig
n
an
t
p
er
ip
h
er
al
n
er
v
e
sh
ea
th
tu
-
m
o
u
r-
M
P
N
S
T
(l
if
et
im
e
ri
sk
8
-1
3
%
),
B
re
as
t
ca
n
ce
r
(l
if
et
im
e
ri
sk
8
.4
%
),
G
IS
T
s
(l
if
et
im
e
ri
sk
6
%
),
as
tr
o
cy
to
m
a:
o
p
ti
c-
p
at
h
w
ay
g
li
o
m
a
(p
re
v
al
en
ce
5
-2
5
%
),
P
h
ae
o
ch
ro
m
o
cy
to
m
a
(p
re
v
a-
le
n
ce
1
%
).
N
F
1
A
D
w
it
h
ex
tr
em
el
y
v
ar
ia
b
le
ex
p
re
ss
iv
i-
ty
,
ev
en
w
it
h
in
a
fa
m
il
y
.
5
0
%
d
e
n
o
v
o
.
2
5
1
2
6
0
N
ij
m
eg
en
B
re
ak
ag
e
S
y
n
d
ro
m
e
1
*
*
N
o
n
-H
o
d
g
k
in
ly
m
p
h
o
m
a,
le
u
k
em
ia
,
m
ed
u
ll
o
b
la
st
o
m
a,
rh
ab
d
o
m
y
o
sa
rc
o
m
a.
N
B
S
1
A
R
1
6
3
9
5
0
N
o
o
n
an
S
y
n
d
ro
m
e
1
;
N
S
1
5
0
L
eu
k
em
ia
(J
M
M
L
,
A
L
L
,
C
M
M
L
)
an
d
m
al
ig
n
an
t
sc
h
w
an
n
o
m
a.
.
P
T
P
N
1
1
(5
9
%
),
S
O
S
1
(1
3
%
),
R
A
F
1
(3
-1
7
%
)
an
d
K
R
A
S
(<
5
%
)
g
en
es
.
A
D
w
it
h
v
ar
ia
b
le
ex
p
re
ss
iv
it
y
.
U
su
al
ly
o
cc
u
rs
b
y
d
e
n
o
v
o
m
u
ta
ti
o
n
s.
2
6
7
0
0
0
P
er
lm
an
S
y
n
d
ro
m
e
<
0
.0
1
B
il
at
er
al
re
n
al
h
am
ar
to
m
as
,
W
il
m
s
tu
-
m
o
r
D
IS
3
L
2
A
R
T
a
b
le
1
(c
o
n
t.
)
246 Lapunzina et al.
O
M
IM
S
y
n
d
ro
m
e
P
re
v
al
en
ce
(/
1
0
0
.0
0
0
)
T
u
m
o
rs
E
ti
o
lo
g
y
H
er
ed
it
y
2
6
8
4
0
0
R
o
th
m
u
n
d
-T
h
o
m
so
n
S
y
n
d
ro
m
e;
R
T
S
<
0
.0
1
O
st
eo
sa
rc
o
m
a,
b
as
al
ce
ll
ca
rc
in
o
m
a
an
d
sq
u
am
o
u
s
ce
ll
ca
rc
in
o
m
a.
R
E
C
Q
L
4
A
R
1
8
0
8
4
9
R
u
b
in
st
ei
n
-T
ay
b
i
S
y
n
d
ro
m
e;
R
S
T
S
0
.6
*
*
L
eu
k
em
ia
,
m
en
in
g
io
m
as
,
n
eu
ro
b
la
st
o
-
m
a,
rh
ab
d
o
m
y
o
sa
rc
o
m
a,
as
tr
o
cy
to
m
a,
m
ed
u
ll
o
b
la
st
o
m
a,
O
li
g
o
d
en
d
ro
g
li
o
m
a,
ch
o
ri
st
o
m
a,
se
m
in
o
m
a,
p
in
ea
l
g
la
n
d
tu
-
m
o
u
r.
C
R
E
B
B
P
(3
0
%
)
an
d
E
P
3
0
0
(3
%
).
M
ic
ro
d
el
et
io
n
s
1
0
%
.
A
D
.
U
su
al
ly
o
cc
u
rs
b
y
d
e
n
o
v
o
m
u
ta
-
ti
o
n
s.
2
6
9
1
5
0
S
ch
in
ze
l-
G
ie
d
io
n
M
id
fa
ce
-R
et
ra
ct
io
n
S
y
n
d
ro
m
e
<
0
.0
1
E
m
b
ry
o
n
al
tu
m
o
rs
,
h
ep
at
o
b
la
st
o
-
m
a,
sa
cr
o
co
cc
y
g
ea
l
te
ra
to
m
a.
S
E
T
B
P
1
A
D
2
2
4
7
5
0
S
ch
o
p
f-
S
ch
u
lz
-P
as
sa
rg
e
S
y
n
d
ro
m
e
<
0
.0
1
B
as
al
ce
ll
ca
rc
in
o
m
a,
sq
u
am
o
u
s
ce
ll
ca
rc
in
o
m
a.
W
N
T
1
0
A
A
R
2
6
0
4
0
0
S
h
w
ac
h
m
an
-D
ia
m
o
n
d
S
y
n
d
ro
m
e;
S
D
S
<
0
.0
1
A
M
L
,
M
D
S
,
o
st
eo
sa
rc
o
m
a.
S
B
D
S
(9
0
%
p
re
se
n
t
g
en
e
co
n
v
er
si
o
n
in
o
n
e
al
le
le
s)
A
R
1
8
0
8
6
0
S
il
v
er
-R
u
ss
el
l
S
y
n
d
ro
m
e;
S
R
S
0
.8
*
*
C
ra
n
io
p
h
ar
y
n
g
io
m
a,
te
st
ic
u
la
r
se
m
i-
n
o
m
a,
W
il
m
s
tu
m
o
r,
h
ep
at
o
ca
rc
in
o
m
a.
D
N
A
h
y
p
o
m
et
h
y
la
ti
o
n
at
th
e
te
lo
m
er
ic
im
p
ri
n
ti
n
g
co
n
tr
o
l
re
g
io
n
(I
C
R
1
)
o
n
1
1
p
1
5
,
in
v
o
lv
in
g
th
e
H
1
9
an
d
IG
F
2
g
en
es
.
S
p
o
ra
d
ic
3
1
2
8
7
0
S
im
p
so
n
-G
o
la
b
i-
B
eh
m
el
S
y
n
-
d
ro
m
e,
T
Y
P
E
1
;
S
G
B
S
1
<
0
.0
1
H
ep
at
o
b
la
st
o
m
a,
W
il
m
s’
tu
m
o
r,
n
eu
-
ro
b
la
st
o
m
a.
G
P
C
3
(4
0
-7
0
%
)
X
-l
in
k
ed
1
1
7
5
5
0
S
o
to
s
S
y
n
d
ro
m
e
0
.3
*
*
L
eu
k
em
ia
,
ly
m
p
h
o
m
a,
W
il
m
s’
tu
-
m
o
u
r,
sa
cr
o
co
cc
y
g
ea
l
te
ra
to
m
a,
n
eu
ro
-
b
la
st
o
m
a.
N
S
D
1
(S
T
O
)
(8
5
%
):
In
tr
ag
en
ic
m
u
ta
-
ti
o
n
s
(7
0
-9
0
%
)
an
d
d
el
et
io
n
s/
d
u
p
li
ca
-
ti
o
n
s
(1
5
-3
0
%
).
A
D
.
U
su
al
ly
o
cc
u
rs
b
y
d
e
n
o
v
o
m
u
ta
-
ti
o
n
s
(9
5
%
).
1
9
1
1
0
0
T
u
b
er
o
u
s
S
cl
er
o
si
s;
T
S
C
1
A
N
D
T
S
C
2
8
.8
R
et
in
al
h
am
ar
to
m
as
,
ca
rd
ia
c
rh
ab
d
o
-
m
y
o
m
a,
re
n
al
an
g
io
m
y
o
li
p
o
m
as
,
g
ia
n
t
ce
ll
as
tr
o
cy
to
m
as
.
T
S
C
1
(1
0
-3
0
%
)
o
r
T
S
C
2
(7
0
-9
0
%
)
g
en
es
.
A
D
.
A
d
e
n
o
v
o
m
u
ta
ti
o
n
is
fo
u
n
d
in
6
5
%
o
f
th
e
ca
se
s.
2
7
6
7
0
0
T
y
ro
si
n
em
ia
,
T
Y
P
E
I
0
.0
5
H
ep
at
o
m
a.
F
A
H
m
o
le
cu
la
r
g
en
et
ic
an
al
y
si
s
d
et
ec
t
fo
u
r
co
m
m
o
n
m
u
ta
ti
o
n
s
in
9
5
%
o
f
af
-
fe
ct
ed
in
d
iv
id
u
al
s
(I
V
S
1
2
+
5
G
>
A
,
IV
S
6
-1
G
>
T
,
IV
S
7
-6
T
>
G
,
an
d
P
2
6
1
L
).
A
R
.
C
ar
ri
er
fr
eq
u
en
cy
:
1
:1
5
0
to
1
:1
0
0
.
2
7
7
7
0
0
W
er
n
er
S
y
n
d
ro
m
e;
W
R
N
0
.4
5
M
al
ig
n
an
cy
in
ap
p
ro
x
im
at
el
y
1
0
%
.
T
h
y
ro
id
n
eo
p
la
sm
s,
m
el
an
o
m
a,
so
ft
ti
s-
su
e
sa
rc
o
m
as
,
h
em
at
o
lo
g
ic
/l
y
m
p
h
o
id
n
eo
p
la
sm
s,
o
st
eo
sa
rc
o
m
a
an
d
m
en
in
-
g
io
m
a.
R
E
C
Q
L
2
A
R
2
7
8
7
0
0
,
6
1
0
6
5
1
,
m
u
lt
ip
le
X
er
o
d
er
m
a
P
ig
m
en
to
su
m
0
.2
3
C
u
ta
n
eo
u
s
b
as
al
ce
ll
ca
rc
in
o
m
a,
sq
u
a-
m
o
u
s
ce
ll
ca
rc
in
o
m
a,
m
el
an
o
m
a,
an
g
io
-
sa
rc
o
m
a,
fi
b
ro
x
an
th
o
m
a.
A
ss
o
ci
at
ed
w
it
h
m
u
ta
ti
o
n
s
in
X
P
A
,
E
R
C
C
3
,
X
P
C
,
E
R
C
C
2
,
D
D
B
2
,
E
R
C
C
4
,
E
R
C
C
5
,
E
R
C
C
1
,
an
d
P
O
L
H
g
en
es
.
A
R
P
re
v
al
en
ce
o
b
ta
in
ed
fr
o
m
:
O
rp
h
an
et
R
ep
o
rt
S
er
ie
s
-
P
re
v
al
en
ce
o
f
ra
re
d
is
ea
se
s:
B
ib
li
o
g
ra
p
h
ic
d
at
a
-
N
o
v
em
b
er
2
0
1
3
-
N
u
m
b
er
1
.
*
*
P
re
v
al
en
ce
at
b
ir
th
.
T
a
b
le
1
(c
o
n
t.
)
tion (~55%) than in those possessing the G12S mutation
(~5%). The greatest potential for malignant transformation
has been observed with the G12V mutation; it is the most
common mutation in sporadic tumors, although it has not
been detected in Costello syndrome patients (Aoki et al.,
2005). In general, the spectrum of mutations causing
germ-line RASopathies is different than those causing tu-
mors; however, there is a greater overlap compared to mo-
saic RASophaties (Hafner and Groesser, 2013).
Another well-known tumor suppressor gene involved
in the pathogenesis of developmental syndromes is PTEN
(Mester and Eng, 2013). This gene modulates the
AKT/PI3K/mTOR and MAPK pathways that inhibit prolif-
eration and promote cell death. Genetic and epigenetic in-
activations of PTEN are frequently found in a variety of
tumor types, and PTEN mutations are responsible for the
pathogenesis of the PTEN hamartoma tumor syndromes
(PHTS) that are characterized by overgrowth and multiple
hamartomas. PHTS include Cowden syndrome and Ban-
nayan-Riley-Ruvalcaba syndrome, both of which demon-
strate a 25-50% and 10% lifetime risk of developing breast
and thyroid cancer, respectively, as well as PTEN-related
Proteus syndrome and Proteus-like syndrome. PTEN is a
natural inhibitor of AKT1, an oncogenic kinase that acts
downstream of PI3K to control proliferation and survival.
Activating mutations in the AKT1 gene that are likely only
tolerated in a mosaic state cause Proteus syndrome, the
main differential diagnosis of PHTS, and are characterized
by segmental manifestations. Tumors are not the main fea-
ture of Proteus syndrome, but additional somatic mutations
may lead to cancer development.
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Figure 1 - Phenotypic presentations in some genetic developmental syndromes that have an increased risk of developing cancer. (A) Beckwith-
Wiedemann. (B) Costello. (C) Simpson-Golabi-Behmel. (D) Noonan. (E) Hemihyperplasia. (F) NF1. (G) Rubinstein-Taybi. (H) Megalencephaly-
Capillary Malformation.
Figure 2 - Known and predicted associations between major genetic de-
velopmental syndromes with an increased risk of developing cancer using
the Search Tool for the Retrieval of Interacting Genes/Proteins (STRING)
database of physical and functional interactions version 9.1 (Jensen et al.,
2009). Disconnected nodes are not shown. Xeroderma Pigmentosum, Dia-
mond-Blackfan anemia and Fanconi anemia were simplified to one gene
for visual purposes. Lines connecting nodes represents association due to
coexpression (black), coocurrence (dark blue), experiments (pink), data-
bases (light blue), text mining (green), and homology (purple).
Further downstream in the AKT/PI3K/mTOR path-
way is the PIK3CA oncogene, which has been frequently
implicated in various neoplasms, including breast, lung and
cervical cancer. The helicase and kinase domains of this
protein are hot spots for somatic mutations associated with
PIK3CA gain of function mutations and cancer. Mutations
in PIK3CA are also involved in segmental overgrowth syn-
dromes, such as Megalencephaly-Capillary Malformation
(M-CM), Hemimegalencephaly, and CLOVES. In M-CM
patients, mutations in PIK3CA are most often de novo and
somatically mosaic, suggesting that the mutation occurred
in the embryo post-fertilization. Mutations in PIK3CA as-
sociated with M-CM are not usually found in cancers, con-
trary to what has been observed for Hemimegalencephaly
and CLOVES syndromes in which mutations related to
cancer in PIK3CA hot spots have been reported (Mirzaa et
al., 2013).
Although it is not an OGS but still affects the
AKT/PI3K/mTOR pathway, Tuberous Sclerosis Complex
(TSC) is a disorder caused by inactivating mutations in ei-
ther the TSC1 or TSC2 tumor suppressor genes responsible
for inhibiting mTOR, another pathway often activated in
human cancers. TSC is characterized by the presence of
hamartomatous lesions in several organs throughout the
body and is accompanied by seizures, intellectual disabil-
ity, and renal and pulmonary disease. TSC tumors may de-
velop in any tissue, including the brain (cortical tubers,
subependymal nodules and subependymal giant cell astro-
cytomas), heart (cardiac rhabdomyoma), kidney (angio-
myolipomas and renal cysts), or liver (angiomyolipomas
and hepatic hamartomas) (Borkowska et al., 2011).
Blood/breakage syndromes
The stability and integrity of DNA is essential for cel-
lular and organismal survival. Consequently, DNA repair
mechanisms are mediated by multiple molecular pathways,
use different enzymes to act on different injuries (environ-
mental damage, DNA replication errors, etc.) and are es-
sential for preventing deleterious mutations and genetic
instability.
Emergence of cancers is a natural consequence of
mutations to DNA repair mechanisms; however, when
germ-line mutations affecting repair mechanisms occur,
they give rise to complex developmental disorders charac-
terized by premature aging and/or increased risk of cancer,
such as Ataxia Telangiectasia, Bloom Syndrome, Fanconi
anemia, Nijmegen Breakage syndrome, Werner syndrome,
and Xeroderma Pigmentosum, the last of which leads to a
10,000-fold increase in risk of non-melanoma skin cancer
and a 2,000-fold increased risk of melanoma (Knoch et al.,
2012).
ATM (related to ataxia telangiectasia) is involved in
damage-induced repair of specific DNA double-strand
breaks (DSB) and in the activation and regulation of many
pathways, including p53-dependent apoptosis. NBS1
(Nijmegen Breakage syndrome) plays an important role as
a DNA DSB sensor and activator of ATM. The XP-proteins
(Xeroderma Pigmentosum) are involved in nucleotide exci-
sion repair as well as in transcription as chromatin remodel-
ing factors. WRN (Werner syndrome) and BLM (Bloom
syndrome) belong to the family of RecQ helicases; the for-
mer plays multiple roles in DSB-repair, base excision re-
pair, and telomere maintenance, while the latter is involved
in damage recognition, homologous recombination, chro-
mosome integrity, cell division, and chromatin remodeling.
The genes involved in Fanconi anemia-pathway play a role
in DNA repair, interstrand-crosslink repair and telomere
maintenance (Knoch et al., 2012). Another developmental
syndrome, Rothmund-Thomson syndrome, is also caused
by mutations in a RecQ helicase (RECQL4), but it is not
usually included in the breakage syndromes despite being
one of its main differential diagnoses. Rothmund-Thomson
syndrome is characterized by poikiloderma, telangiectasia,
congenital skeletal abnormalities, premature aging, and in-
creased risk of malignant disease, especially osteosarcoma.
Finally, we have included some disorders associated
with lymphohematologic alterations in this cluster due to
their characteristics and types of neoplasm. As happens in
Fanconi anemia, and which are included in its differential
diagnosis, Diamond-Blackfan anemia and Shwachman-
Diamond syndrome are rare diseases involving bone mar-
row failure, congenital malformations and increased risk of
developing tumors, primarily acute myelogenous leuke-
mia, myelodysplastic syndrome and some solid tumors,
such as osteogenic sarcoma. Diamond-Blackfan anemia is
caused by mutations in the RPS19 gene encoding a ribo-
somal protein, while Shwachman-Diamond syndrome is
caused by mutations in the SBDS gene encoding a protein
that might have roles in RNA metabolism and ribosome
biogenesis.
Other syndromes
Some classic developmental syndromes do not form
large evident clusters; however, they do show an increased
risk of developing cancer and, in some cases, have relation-
ships to one another, the significance of which have yet to
be defined (Figure 1). The most noteworthy cluster is
Aniridia/WAGR: its primary neoplasm, Wilms tumor, is
present in many overgrowth syndromes, and it is directly
associated with hypermethylation of the imprinting center
1, genomic abnormalities and uniparental disomy in chro-
mosome region 11p15, all causing Beckwith-Wiedemann
syndrome.
Using the STRING database (Jensen et al., 2009) to
look for physical and functional protein interactions,
NOTCH2 (Alagille syndrome) and CREBBP (Rubinstein
Taybi syndrome) share predicted functional links when
testing for homology, searching databases and text mining.
Rubinstein Taybi syndrome (CREBBP and EP300) is asso-
ciated with Aniridia/WAGR (PAX6 and WT1) by experi-
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ments and data mining and has been related to Werner
(WRN), Rothmund-Thomson (RECQL4) and Nijmegen
Breakage (NBS1) syndromes by testing for homology, ex-
periments, and text mining. Although the interactions pre-
dicted by this database have limitations, they are a useful
starting point for future studies.
Final Considerations
Studies in patients and families with cancer predispo-
sition and developmental syndromes have allowed us to un-
derstand not only tumors arising in hereditary cancers but
also to understand cancer as a genetic disease of somatic
cells. The spectrum of disorders ranging from pure devel-
opmental syndromes through intermediate states, such as
cancer predisposition syndromes with a varied presence of
congenital malformations to sporadic cancer, seems to be a
continuous line drawn by numerous interconnected molec-
ular pathways. A deeper understanding of these alterations
is making possible the use of molecular targets associated
with genetic syndromes in the treatment of sporadic tu-
mors, and in the future, may even allow the use of the drugs
used in oncology for the management of developmental
disorders. (Bellacosa, 2013).
No less important, physicians and especially clinical
geneticists and oncologists should be aware of the exis-
tence of these sometimes rare syndromes and their high risk
of developing tumors. This knowledge is essential for mak-
ing a correct diagnosis and for monitoring and treating pa-
tients. The new high-throughput technologies have enabled
us to establish diagnostic and research tests for syndromes
that often have overlapping clinical manifestations and are
caused by multiple genes and mechanisms. With a bit of en-
thusiasm and determination, the expectations raised with
the acquired knowledge and use of new technologies will
be met in the near future.
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